JOY BRIGHT-AGINDOTAN: Open Payments
NPI 1184004178 · WASHINGTON, DC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$788 in 24 payments from 10 companies in 2025. Trend: 2023 $20 · 2024 $28 · 2025 $788
Food & beverage: $788
| Company | Payments | Amount |
|---|---|---|
| Madrigal Pharmaceuticals | 2 | $161 |
| Gilead Sciences, Inc. | 3 | $157 |
| Janssen Biotech, Inc. | 5 | $113 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 4 | $92 |
| Ipsen Biopharmaceuticals, Inc | 3 | $69 |
| PFIZER INC. | 2 | $62 |
| Lilly USA, LLC | 2 | $57 |
| ABBVIE INC. | 1 | $29 |
| Novo Nordisk Inc | 1 | $26 |
| Janssen Scientific Affairs, LLC | 1 | $23 |
Products named: REZDIFFRA, TREMFYA, Livdelzi, XIFAXAN, IQIRVO, OMVOH, XELJANZ, LINZESS.
Industry payments across DC — which companies pay providers there.
